GLS-5700, a DNA-based Zika vaccine was demonstrated as safe and effective against zika virus in phase 1 clinical trials, in the latest study published in New England Journal of Medicine. As there is no approved vaccine against zika infection till date, these results give pave ways for further research. Zika virus infection is a public health emergency associated complication such as congenital birth defects and the Guillain–Barré syndrome. There are no approved vaccines against ZIKV infection yet.
The GLS-5700 vaccine contains the synthetic DNA instructions for the host to mount an immune response against a specific Zika virus antigen. This new generation of DNA vaccines can be designed and manufactured rapidly and they are significantly safer and stable than most traditional vaccines. Study Safety and immunogenicity of GLS-5700 vaccine was evaluated in 40 participants. Two groups of 20…
